PDCD1 and neoplasm: Pembrolizumab, a humanized monoclonal anti-PD-1 antibody, demonstrated consistent overall survival (OS) benefit [HR:0.62 (0.48–0.81), median OS 26.3 versus 13.4 months], compared to platinum doublet chemotherapy in patients with PD-L1 expression in more than 50% of tumor cells (PD-L1 > 50%).